Pfizer and Arvinas win UK’s fast track tag for breast cancer drug
Pharmaceutical Technology
AUGUST 1, 2023
Vepdegestrant was awarded the Innovation Passport designation for treating advanced or metastatic breast cancer.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
AUGUST 1, 2023
Vepdegestrant was awarded the Innovation Passport designation for treating advanced or metastatic breast cancer.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content